EL7.AI
StocksUpdated×4•Originally published 28 April 2026•Updated 30 April 2026•
1 min read

OPKO Health Q1 2026 Earnings: Company Reports Loss Amid Stable Revenue

Key Facts

1OPKO Health is projected to report a loss per share of $0.07 and revenue of approximately $130.51 million for Q1 2026.
2The company's revenue streams are supported by its drug RAYALDEE and profit-sharing agreements with Pfizer and Lilly.
3The company maintains strong liquidity with a current ratio of 3.97 and a debt-to-equity ratio of 0.34 despite current unprofitability.

OPKO Health (OPK) released its Q1 2026 financial results, reporting a loss per share of $0.07, aligning with analyst estimates. Revenue reached $130.51 million, a 25.7% year-over-year decline driven by a smaller diagnostics base, though performance remains supported by strategic partnerships. Looking ahead, LPL Financial Holdings Inc. (LPLA) is scheduled to report its Q1 2026 results on April 30, 2026, with consensus estimates projecting an EPS of $5.49 and revenue of $4.98 billion, a 34.9% annual increase. Notably, analysts have revised LPLA's EPS estimates downward by 4.3% over the past 30 days. Additionally, Organon (OGN) and Altria (MO) have issued their Q1 2026 earnings reports to evaluate performance against Wall Street expectations. OPKO continues to maintain a robust balance sheet with a current ratio of 3.97 as investors monitor the broader earnings cycle and its impact on long-term profitability.